Search results
Results from the WOW.Com Content Network
The Yamaha DSP-1 is a processor of early home theater surround sound equipment, produced in 1986. [1] The DSP-1 (referred to by Yamaha as a Digital Soundfield Processor) allowed owners to synthesize up to 6-channels of surround sound from 2 channel stereo sound via a complex digital signal processor (DSP).
The Yamaha PM1000 mixing console was a significant product in the professional audio industry because of its many advanced features and reasonable price. Introduced in 1974 it incorporated many innovative features such as a modular design using channel strips and output strips, a 4 bus design, and an output matrix mixer .
An audio/video receiver (AVR) or a stereo receiver is a consumer electronics component used in a home theater or hi-fi system. Its purpose is to receive audio and video signals from a number of sources, and to process them and provide power amplifiers to drive loudspeakers , and/or route the video to displays such as a television , monitor or ...
Yamaha Corporation (ヤマハ株式会社, Yamaha Kabushiki gaisha, / ˈ j ɑː m ɒ ˌ h ɑː /; Japanese pronunciation:) is a Japanese musical instrument and audio equipment manufacturer. It is one of the constituents of Nikkei 225 and is the world's largest musical instrument manufacturing company.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
U.S. passenger railroad Amtrak said on Tuesday ridership topped 2019 pre-COVID levels for the first time in 2024 and reached a record high even with less capacity. Amtrak reported an adjusted ...
The XG-compatible Yamaha S-YXG50 SoftSynthesizer, which is discontinued, is an entirely software-based MIDI synth. It used a 2 MB or 4 MB wavetable sound set, and was common among non-professional users who needed a cheap, high-quality MIDI synthesizer for purposes such as playing video games that rely on MIDI for their music.
When it comes to blockbuster weight-loss drugs like Wegovy and Ozempic, opinion among some of President-elect Donald Trump’s top advisers and health policy nominees appears deeply split.